Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will participate in a fireside chat at the UBS Global Healthcare Conference from May 23-25, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will participate in a fireside chat at the UBS Global Healthcare Conference from May 23-25, 2022.
The chat is scheduled for May 23 at 1:15 PM ET and will be accessible via webcast on the company's website. Immunovant is dedicated to developing therapies for autoimmune diseases, focusing on its investigational compound, batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +7.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference, taking place May 23rd-25th, 2022.
UBS Global Healthcare Conference fireside chat details:
| Date: | Monday, May 23rd, 2022 | |
| Time: | 1:15pm Eastern Time | |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.